Cardiovascular disease

Cardiovascular disease

Micrograph of a heart with fibrosis (yellow) and amyloidosis (brown). Movat's stain.
Classification and external resources
Specialty Cardiology
ICD-10 I51.6
ICD-9-CM 429.2
DiseasesDB 28808
MeSH D002318

Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels.[1] Cardiovascular disease includes coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack).[1] Other CVDs are stroke, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, endocarditis, aortic aneurysms, peripheral artery disease and venous thrombosis.[1][2]

The underlying mechanisms vary depending on the disease in question. Coronary artery disease, stroke, and peripheral artery disease involve atherosclerosis. This may be caused by high blood pressure, smoking, diabetes, lack of exercise, obesity, high blood cholesterol, poor diet, and excessive alcohol consumption, among others. High blood pressure results in 13% of CVD deaths, while tobacco results in 9%, diabetes 6%, lack of exercise 6% and obesity 5%. Rheumatic heart disease may follow untreated strep throat.[1]

It is estimated that 90% of CVD is preventable.[3] Prevention of atherosclerosis is by decreasing risk factors through: healthy eating, exercise, avoidance of tobacco smoke and limiting alcohol intake.[1] Treating high blood pressure and diabetes is also beneficial.[1] Treating people who have strep throat with antibiotics can decrease the risk of rheumatic heart disease.[4] The effect of the use of aspirin in people who are otherwise healthy is of unclear benefit.[5][6] The United States Preventive Services Task Force recommends against its use for prevention in women less than 55 and men less than 45 years old; however, in those who are older it is recommends in some individuals.[7] Treatment of those who have CVD improves outcomes.[1]

Cardiovascular diseases are the leading cause of death globally.[1] This is true in all areas of the world except Africa.[1] Together they resulted in 17.3 million deaths (31.5%) in 2013 up from 12.3 million (25.8%) in 1990.[2] Deaths, at a given age, from CVD are more common and have been increasing in much of the developing world, while rates have declined in most of the developed world since the 1970s.[8][9] Coronary artery disease and stroke account for 80% of CVD deaths in males and 75% of CVD deaths in females.[1] Most cardiovascular disease affects older adults. In the United States 11% of people between 20 and 40 have CVD, while 37% between 40 and 60, 71% of people between 60 and 80, and 85% of people over 80 have CVD.[10] The average age of death from coronary artery disease in the developed world is around 80 while it is around 68 in the developing world.[8] Disease onset is typically seven to ten years earlier in men as compared to women.[11]

Types

Disability-adjusted life year for inflammatory heart diseases per 100,000 inhabitants in 2004.[12]
  no data
  less than 70
  70–140
  140–210
  210–280
  280–350
  350–420
  420–490
  490–560
  560–630
  630–700
  700–770
  more than 770

There are many cardiovascular diseases involving the blood vessels. They are known as vascular diseases:

There are also many cadiovascular diseases that involve the heart.

Risk factors

There are several risk factors for heart diseases: age, gender, tobacco use, physical inactivity, excessive alcohol consumption, unhealthy diet, obesity, family history of cardiovascular disease, raised blood pressure (hypertension), raised blood sugar (diabetes mellitus), raised blood cholesterol (hyperlipidemia), psychosocial factors, poverty and low educational status, and air pollution.[13][14][15][16][17] While the individual contribution of each risk factor varies between different communities or ethnic groups the overall contribution of these risk factors is very consistent.[18] Some of these risk factors, such as age, gender or family history, are immutable; however, many important cardiovascular risk factors are modifiable by lifestyle change, social change, drug treatment and prevention of hypertension, hyperlipidemia, and diabetes.

Age

Calcified heart of an older woman with cardiomegaly.

Age is by far the most important risk factor in developing cardiovascular or heart diseases, with approximately a tripling of risk with each decade of life.[19] Coronary fatty streaks can begin to form in adolescence.[20] It is estimated that 82 percent of people who die of coronary heart disease are 65 and older.[21] At the same time, the risk of stroke doubles every decade after age 55.[22]

Multiple explanations have been proposed to explain why age increases the risk of cardiovascular/heart diseases. One of them is related to serum cholesterol level.[23] In most populations, the serum total cholesterol level increases as age increases. In men, this increase levels off around age 45 to 50 years. In women, the increase continues sharply until age 60 to 65 years.[23]

Aging is also associated with changes in the mechanical and structural properties of the vascular wall, which leads to the loss of arterial elasticity and reduced arterial compliance and may subsequently lead to coronary artery disease.[24]

Sex

Men are at greater risk of heart disease than pre-menopausal women.[19][25] Once past menopause, it has been argued that a woman's risk is similar to a man's[25] although more recent data from the WHO and UN disputes this.[19] If a female has diabetes, she is more likely to develop heart disease than a male with diabetes.[26]

Coronary heart diseases are 2 to 5 times more common among middle-aged men than women.[23] In a study done by the World Health Organization, sex contributes to approximately 40% of the variation in sex ratios of coronary heart disease mortality.[27] Another study reports similar results finding that gender differences explains nearly half the risk associated with cardiovascular diseases[23] One of the proposed explanations for gender differences in cardiovascular diseases is hormonal difference.[23] Among women, estrogen is the predominant sex hormone. Estrogen may have protective effects through glucose metabolism and hemostatic system, and may have direct effect in improving endothelial cell function.[23] The production of estrogen decreases after menopause, and this may change the female lipid metabolism toward a more atherogenic form by decreasing the HDL cholesterol level while increasing LDL and total cholesterol levels.[23]

Among men and women, there are notable differences in body weight, height, body fat distribution, heart rate, stroke volume, and arterial compliance.[24] In the very elderly, age-related large artery pulsatility and stiffness is more pronounced among women than men.[24] This may be caused by the women's smaller body size and arterial dimensions which are independent of menopause.[24]

Tobacco

Cigarettes are the major form of smoked tobacco.[1] Risks to health from tobacco use result not only from direct consumption of tobacco, but also from exposure to second-hand smoke.[1] Approximately 10% of cardiovascular disease is attributed to smoking;[1] however, people who quit smoking by age 30 have almost as low a risk of death as never smokers.[28]

Physical inactivity

Insufficient physical activity (defined as less than 5 x 30 minutes of moderate activity per week, or less than 3 x 20 minutes of vigorous activity per week) is currently the fourth leading risk factor for mortality worldwide.[1] In 2008, 31.3% of adults aged 15 or older (28.2% men and 34.4% women) were insufficiently physically active.[1] The risk of ischemic heart disease and diabetes mellitus is reduced by almost a third in adults who participate in 150 minutes of moderate physical activity each week (or equivalent).[29] In addition, physical activity assists weight loss and improves blood glucose control, blood pressure, lipid profile and insulin sensitivity. These effects may, at least in part, explain its cardiovascular benefits.[1]

Diet

High dietary intakes of saturated fat, trans-fats and salt, and low intake of fruits, vegetables and fish are linked to cardiovascular risk, although whether all these associations are a cause is disputed. The World Health Organization attributes approximately 1.7 million deaths worldwide to low fruit and vegetable consumption.[1] The amount of dietary salt consumed is also an important determinant of blood pressure levels and overall cardiovascular risk.[1] Frequent consumption of high-energy foods, such as processed foods that are high in fats and sugars, promotes obesity and may increase cardiovascular risk.[1] High trans-fat intake has adverse effects on blood lipids and circulating inflammatory markers,[30] and elimination of trans-fat from diets has been widely advocated.[31] There is evidence that higher consumption of sugar is associated with higher blood pressure and unfavorable blood lipids,[32] and sugar intake also increases the risk of diabetes mellitus.[33] High consumption of processed meats is associated with an increased risk of cardiovascular disease, possibly in part due to increased dietary salt intake.[34]

The relationship between alcohol consumption and cardiovascular disease is complex, and may depend on the amount of alcohol consumed. There is a direct relationship between high levels of alcohol consumption and risk of cardiovascular disease.[1] Drinking at low levels without episodes of heavy drinking may be associated with a reduced risk of cardiovascular disease.[35] Overall alcohol consumption at the population level is associated with multiple health risks that exceed any potential benefits.[1][36]

Socioeconomic disadvantage

Cardiovascular disease affects low- and middle-income countries even more than high-income countries.[37] There is relatively little information regarding social patterns of cardiovascular disease within low- and middle-income countries,[37] but within high-income countries low income and low educational status are consistently associated with greater risk of cardiovascular disease.[38] Policies that have resulted in increased socio-economic inequalities have been associated with greater subsequent socio-economic differences in cardiovascular disease[37] implying a cause and effect relationship. Psychosocial factors, environmental exposures, health behaviours, and health-care access and quality contribute to socio-economic differentials in cardiovascular disease. [39] The Commission on Social Determinants of Health recommended that more equal distributions of power, wealth, education, housing, environmental factors, nutrition, and health care were needed to address inequalities in cardiovascular disease and non-communicable diseases.[40]

Air pollution

Particulate matter has been studied for its short- and long-term exposure effects on cardiovascular disease. Currently, PM2.5 is the major focus, in which gradients are used to determine CVD risk. For every 10 μg/m3 of PM2.5 long-term exposure, there was an estimated 8–18% CVD mortality risk.[41] Women had a higher relative risk (RR) (1.42) for PM2.5 induced coronary artery disease than men (0.90) did.[41] Overall, long-term PM exposure increased rate of atherosclerosis and inflammation. In regards to short-term exposure (2 hours), every 25 μg/m3 of PM2.5 resulted in a 48% increase of CVD mortality risk.[42] In addition, after only 5 days of exposure, a rise in systolic (2.8 mmHg) and diastolic (2.7 mmHg) blood pressure occurred for every 10.5 μg/m3 of PM2.5.[42] Other research has implicated PM2.5 in irregular heart rhythm, reduced heart rate variability (decreased vagal tone), and most notably heart failure.[42][43] PM2.5 is also linked to carotid artery thickening and increased risk of acute myocardial infarction.[42][43]

Cardiovascular risk assessment

Existing cardiovascular disease or a previous cardiovascular event, such as a heart attack or stroke, is the strongest predictor of a future cardiovascular event.[44] Age, sex, smoking, blood pressure, blood lipids and diabetes are important predictors of future cardiovascular disease in people who are not known to have cardiovascular disease.[45] These measures, and sometimes others, may be combined into composite risk scores to estimate an individual's future risk of cardiovascular disease.[44] Numerous risk scores exist although their respective merits are debated.[46] Other diagnostic tests and biomarkers remain under evaluation but currently these lack clear-cut evidence to support their routine use. They include family history, coronary artery calcification score, high sensitivity C-reactive protein (hs-CRP), ankle brachial index, lipoprotein subclasses and particle concentration, lipoprotein(a), apolipoproteins A-I and B, fibrinogen, white blood cell count, homocysteine, N-terminal pro B-type natriuretic peptide (NT-proBNP), and markers of kidney function.[47][48]

Pathophysiology

Density-Dependent Colour Scanning Electron Micrograph SEM (DDC-SEM) of cardiovascular calcification, showing in orange calcium phosphate spherical particles (denser material) and, in green, the extracellular matrix (less dense material).[49]

Population-based studies show that atherosclerosis, the major precursor of cardiovascular disease, begins in childhood. The Pathobiological Determinants of Atherosclerosis in Youth Study demonstrated that intimal lesions appear in all the aortas and more than half of the right coronary arteries of youths aged 7–9 years.[50]

This is extremely important considering that 1 in 3 people die from complications attributable to atherosclerosis. In order to stem the tide, education and awareness that cardiovascular disease poses the greatest threat, and measures to prevent or reverse this disease must be taken.

Obesity and diabetes mellitus are often linked to cardiovascular disease,[51] as are a history of chronic kidney disease and hypercholesterolaemia.[52] In fact, cardiovascular disease is the most life-threatening of the diabetic complications and diabetics are two- to four-fold more likely to die of cardiovascular-related causes than nondiabetics.[53][54][55]

Screening

Screening ECGs (either at rest or with exercise) are not recommended in those without symptoms who are at low risk.[56] This includes those who are young without risk factors.[57] In those at higher risk the evidence for screening with ECGs is inconclusive.[56]

Additionally echocardiography, myocardial perfusion imaging, and cardiac stress testing is not recommended in those at low risk who do not have symptoms.[58]

Some biomarkers may add to conventional cardiovascular risk factors in predicting the risk of future cardiovascular disease; however, the clinical value of some biomarkers is questionable.[59][60]

Prevention

Currently practiced measures to prevent cardiovascular disease include:

For adults without a known diagnosis of hypertension, diabetes, hyperlipidemia, or cardiovascular disease, routine counseling to advise them to improve their diet and increase their physical activity has not been found to significantly alter behavior, and thus is not recommended.[77] It is unclear whether or not dental care in those with periodontitis affects the risk of cardiovascular disease.[78] Exercise in those who are at high risk of heart disease has not been well studied as of 2014.[79]

Diet

A diet high in fruits and vegetables decreases the risk of cardiovascular disease and death.[63] Evidence suggests that the Mediterranean diet may improve cardiovascular outcomes.[80] There is also evidence that a Mediterranean diet may be more effective than a low-fat diet in bringing about long-term changes to cardiovascular risk factors (e.g., lower cholesterol level and blood pressure).[81] The DASH diet (high in nuts, fish, fruits and vegetables, and low in sweets, red meat and fat) has been shown to reduce blood pressure,[82] lower total and low density lipoprotein cholesterol[83] and improve metabolic syndrome;[84] but the long-term benefits outside the context of a clinical trial have been questioned.[85] A high fiber diet appears to lower the risk.[86]

Total fat intake does not appear to be an important risk factor.[87][88] A diet high in trans fatty acids, however, does appear to increase rates of cardiovascular disease.[88][89] Worldwide, dietary guidelines recommend a reduction in saturated fat.[90] However, there are some questions around the effect of saturated fat on cardiovascular disease in the medical literature.[89][91] Reviews from 2014 and 2015 did not find evidence of harm from saturated fats.[89][91] A 2012 Cochrane review found suggestive evidence of a small benefit from replacing dietary saturated fat by unsaturated fat.[92] A 2013 meta analysis concludes that substitution with omega 6 linoleic acid (a type of unsaturated fat) may increase cardiovascular risk.[90] Replacement of saturated fats with carbohydrates does not change or may increase risk.[93][94] Benefits from replacement with polyunsaturated fat appears greatest;[88][95] however, supplementation with omega-3 fatty acids (a type of polysaturated fat) does not appear to have an effect.[96]

The effect of a low-salt diet is unclear. A Cochrane review concluded that any benefit in either hypertensive or normal-tensive people is small if present.[97] In addition, the review suggested that a low-salt diet may be harmful in those with congestive heart failure.[97] However, the review was criticized in particular for not excluding a trial in heart failure where people had low-salt and -water levels due to diuretics.[98] When this study is left out, the rest of the trials show a trend to benefit.[98][99] Another review of dietary salt concluded that there is strong evidence that high dietary salt intake increases blood pressure and worsens hypertension, and that it increases the number of cardiovascular disease events; the latter happen both through the increased blood pressure and, quite likely, through other mechanisms.[100][101] Moderate evidence was found that high salt intake increases cardiovascular mortality; and some evidence was found for an increase in overall mortality, strokes, and left ventricular hypertrophy.[100]

Medication

Aspirin has been found to be of only modest benefit in those at low risk of heart disease as the risk of serious bleeding is almost equal to the benefit with respect to cardiovascular problems.[102] In those at really low risk it is not recommended.[103]

Statins are effective in preventing further cardiovascular disease in people with a history of cardiovascular disease.[104] As the event rate is higher in men than in women, the decrease in events is more easily seen in men than women.[104] In those without cardiovascular disease but risk factors statins appear to also be beneficial with a decrease in the risk of death and further heart disease.[105] A United States guideline recommends statins in those who have a 12% or greater risk of cardiovascular disease over the next ten years.[106]

The time course over which statins provide prevention against death appears to be long, of the order of one year, which is much longer than the duration of their effect on lipids.[107] The medications niacin, fibrates and CETP Inhibitors, while they may increase HDL cholesterol do not affect the risk of cardiovascular disease in those who are already on statins.[108]

The use of vasoactive agents for people with pulmonary hypertension with left heart disease or hypoxemic lung diseases may cause harm and unnecessary expense.[109]

Supplements

While a healthy diet is beneficial, in general the effect of antioxidant supplementation (vitamin E, vitamin C, etc.) or vitamins has not been shown to protection against cardiovascular disease and in some cases may possibly result in harm.[110][111] Mineral supplements have also not been found to be useful.[112] Niacin, a type of vitamin B3, may be an exception with a modest decrease in the risk of cardiovascular events in those at high risk.[113][114] Magnesium supplementation lowers high blood pressure in a dose dependent manner.[115] Magnesium therapy is recommended for patients with ventricular arrhythmia associated with torsades de pointes who present with long QT syndrome as well as for the treatment of patients with digoxin intoxication-induced arrhythmias.[116] Evidence to support omega-3 fatty acid supplementation is lacking.[117]

Management

Cardiovascular disease is treatable with initial treatment primarily focused on diet and lifestyle interventions.[1]

Epidemiology

Disability-adjusted life year for cardiovascular diseases per 100,000 inhabitants in 2004.[118]
  no data
  <900
  900-1650
  1650-2300
  2300-3000
  3000-3700
  3700-4400
  4400-5100
  5100-5800
  5800-6500
  6500-7200
  7200–7900
  >7900

Cardiovascular diseases are the leading cause of death. In 2008, 30% of all global death is attributed to cardiovascular diseases. Death caused by cardiovascular diseases are also higher in low- and middle-income countries as over 80% of all global death caused by cardiovascular diseases occurred in those countries. It is also estimated that by 2030, over 23 million people will die from cardiovascular diseases each year.

It is estimated that 60% of the world's cardiovascular disease burden will occur in the South Asian subcontinent despite only accounting for 20% of the world's population. This may be secondary to a combination of genetic predisposition and environmental factors. Organizations such as the Indian Heart Association are working with the World Heart Federation to raise awareness about this issue.[119]

Research

The first studies on cardiovascular health were performed in year 1949 by Jerry Morris using occupational health data and were published in year 1958.[120] The causes, prevention, and/or treatment of all forms of cardiovascular disease remain active fields of biomedical research, with hundreds of scientific studies being published on a weekly basis.

A fairly recent emphasis is on the link between low-grade inflammation that hallmarks atherosclerosis and its possible interventions. C-reactive protein is a common inflammatory marker that has been found to be present in increased levels in patients who are at risk for cardiovascular disease.[121] Also osteoprotegerin, which is involved with regulation of a key inflammatory transcription factor called NF-κB, has been found to be a risk factor of cardiovascular disease and mortality.[122][123]

Some areas currently being researched include the possible links between infection with Chlamydophila pneumoniae (a major cause of pneumonia) and coronary artery disease. The Chlamydia link has become less plausible with the absence of improvement after antibiotic use.[124]

Several research also investigated the benefits of melatonin on cardiovascular diseases prevention and cure. Melatonin is a pineal gland secretion and it is shown to be able to lower total cholesterol, very-low-density and low-density lipoprotein cholesterol levels in the blood plasma of rats. Reduction of blood pressure is also observed when pharmacological doses are applied. Thus, it is deemed to be a plausible treatment for hypertension. However, further research needs to be conducted to investigate the side-effects, optimal dosage, etc. before it can be licensed for use.[125]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Shanthi Mendis; Pekka Puska; Bo Norrving; World Health Organization (2011). Global Atlas on Cardiovascular Disease Prevention and Control (PDF). World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization. pp. 3–18. ISBN 978-92-4-156437-3.
  2. 1 2 GBD 2013 Mortality and Causes of Death, Collaborators (17 December 2014). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.". Lancet 385 (9963): 117–71. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604. PMID 25530442.
  3. ↑ McGill HC, McMahan CA, Gidding SS (March 2008). "Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study". Circulation 117 (9): 1216–27. doi:10.1161/CIRCULATIONAHA.107.717033. PMID 18316498.
  4. ↑ Spinks, A; Glasziou, PP; Del Mar, CB (5 November 2013). "Antibiotics for sore throat.". The Cochrane database of systematic reviews 11: CD000023. doi:10.1002/14651858.CD000023.pub4. PMID 24190439.
  5. ↑ Sutcliffe, P; Connock, M; Gurung, T; Freeman, K; Johnson, S; Ngianga-Bakwin, K; Grove, A; Gurung, B; Morrow, S; Stranges, S; Clarke, A (2013). "Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials.". PLOS ONE 8 (12): e81970. doi:10.1371/journal.pone.0081970. PMID 24339983.
  6. ↑ Sutcliffe, P; Connock, M; Gurung, T; Freeman, K; Johnson, S; Kandala, NB; Grove, A; Gurung, B; Morrow, S; Clarke, A (September 2013). "Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.". Health technology assessment (Winchester, England) 17 (43): 1–253. doi:10.3310/hta17430. PMID 24074752.
  7. ↑ US Preventive Services Task, Force (17 March 2009). "Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.". Annals of Internal Medicine 150 (6): 396–404. doi:10.7326/0003-4819-150-6-200903170-00008. PMID 19293072.
  8. 1 2 Fuster, Board on Global Health ; Valentin; Academies, Bridget B. Kelly, editors ; Institute of Medicine of the National (2010). Promoting cardiovascular health in the developing world : a critical challenge to achieve global health. Washington, D.C.: National Academies Press. pp. Chapter 2. ISBN 978-0-309-14774-3.
  9. ↑ Moran, AE; Forouzanfar, MH; Roth, GA; Mensah, GA; Ezzati, M; Murray, CJ; Naghavi, M (8 April 2014). "Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study.". Circulation 129 (14): 1483–92. doi:10.1161/circulationaha.113.004042. PMID 24573352.
  10. ↑ Go, AS; Mozaffarian, D; Roger, VL; Benjamin, EJ; Berry, JD; Borden, WB; Bravata, DM; Dai, S; Ford, ES; Fox, CS; Franco, S; Fullerton, HJ; Gillespie, C; Hailpern, SM; Heit, JA; Howard, VJ; Huffman, MD; Kissela, BM; Kittner, SJ; Lackland, DT; Lichtman, JH; Lisabeth, LD; Magid, D; Marcus, GM; Marelli, A; Matchar, DB; McGuire, DK; Mohler, ER; Moy, CS; Mussolino, ME; Nichol, G; Paynter, NP; Schreiner, PJ; Sorlie, PD; Stein, J; Turan, TN; Virani, SS; Wong, ND; Woo, D; Turner, MB; American Heart Association Statistics Committee and Stroke Statistics, Subcommittee (1 January 2013). "Heart disease and stroke statistics--2013 update: a report from the American Heart Association.". Circulation 127 (1): e6–e245. doi:10.1161/cir.0b013e31828124ad. PMID 23239837.
  11. ↑ Mendis, Shanthi; Puska,, Pekka; Norrving, Bo (2011). Global atlas on cardiovascular disease prevention and control (1 ed.). Geneva: World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization. p. 48. ISBN 9789241564373. Missing |last1= in Authors list (help)
  12. ↑ "WHO Disease and injury country estimates". World Health Organization. 2009. Retrieved Nov 11, 2009.
  13. ↑ Bridget B. Kelly; Institute of Medicine; Fuster, Valentin (2010). Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health. Washington, D.C: National Academies Press. ISBN 0-309-14774-3.
  14. ↑ Howard, BV; Wylie-Rosett, J (Jul 23, 2002). "Sugar and cardiovascular disease: A statement for healthcare professionals from the Committee on Nutrition of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association.". Circulation 106 (4): 523–7. doi:10.1161/01.cir.0000019552.77778.04. PMID 12135957.
  15. ↑ Finks, SW; Airee, A; Chow, SL; Macaulay, TE; Moranville, MP; Rogers, KC; Trujillo, TC (April 2012). "Key articles of dietary interventions that influence cardiovascular mortality.". Pharmacotherapy 32 (4): e54–87. doi:10.1002/j.1875-9114.2011.01087.x. PMID 22392596.
  16. ↑ Micha, R; Michas, G; Mozaffarian, D (Dec 2012). "Unprocessed red and processed meats and risk of coronary artery disease and type 2 diabetes—an updated review of the evidence.". Current atherosclerosis reports 14 (6): 515–24. doi:10.1007/s11883-012-0282-8. PMC 3483430. PMID 23001745.
  17. ↑ Shanthi Mendis; Pekka Puska; Bo Norrving (2011). Global Atlas on Cardiovascular Disease Prevention and Control. World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization. ISBN 978-92-4-156437-3.
  18. ↑ Yusuf S, Hawken S, Ounpuu S; et al. (2004). "Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study". Lancet 364 (9438): 937–52. doi:10.1016/S0140-6736(04)17018-9. PMID 15364185.
  19. 1 2 3 Finegold, JA; Asaria, P; Francis, DP (Dec 4, 2012). "Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations.". International journal of cardiology 168 (2): 934–945. doi:10.1016/j.ijcard.2012.10.046. PMID 23218570.
  20. ↑ D'Adamo, E; Guardamagna, O; Chiarelli, F; Bartuli, A; Liccardo, D; Ferrari, F; Nobili, V (2015). "Atherogenic dyslipidemia and cardiovascular risk factors in obese children.". International journal of endocrinology 2015: 912047. doi:10.1155/2015/912047. PMC 4309297. PMID 25663838.
  21. ↑ "Understand Your Risk of Heart Attack". American Heart Association.http://www.heart.org/HEARTORG/Conditions/HeartAttack/UnderstandYourRiskofHeartAttack/Understand-Your-Risk-of-Heart-Attack_UCM_002040_Article.jsp#
  22. ↑ Mackay, Mensah, Mendis, et al. The Atlas of Heart Disease and Stroke. World Health Organization. January 2004.
  23. 1 2 3 4 5 6 7 Jousilahti Vartiainen, Tuomilehto Puska (1999). "Sex, Age, Cardiovascular Risk Factors, and coronary heart disease". Circulation 99 (9): 1165–1172. doi:10.1161/01.cir.99.9.1165.
  24. 1 2 3 4 Jani B, Rajkumar C (2006). "Ageing and vascular ageing". Postgrad Med J 82 (968): 357–362. doi:10.1136/pgmj.2005.036053.
  25. 1 2 http://www.world-heart-federation.org/cardiovascular-health/cardiovascular-disease-risk-factors
  26. ↑ "Diabetes raises women's risk of heart disease more than for men". NPR.org. May 22, 2014. Retrieved May 23, 2014.
  27. ↑ Jackson R, Chambles L, Higgins M, Kuulasmaa K, Wijnberg L, Williams D (WHO MONICA Project, and ARIC Study.) Sex difference in ischaemic heart disease mortality and risk factors in 46 communities: an ecologic analysis. Cardiovasc Risk Factors. 1999; 7:43–54.
  28. ↑ Richard Doll, Richard Peto, Jillian Boreham & Isabelle Sutherland (June 2004). "Mortality in relation to smoking: 50 years' observations on male British doctors". BMJ (Clinical research ed.) 328 (7455): 1519. doi:10.1136/bmj.38142.554479.AE. PMC 437139. PMID 15213107.
  29. ↑ World Health Organization; UNAIDS (1 January 2007). Prevention of Cardiovascular Disease. World Health Organization. pp. 3–. ISBN 978-92-4-154726-0.
  30. ↑ Booker, C.S.; Mann, J.I. (2008). "Trans fatty acids and cardiovascular health: Translation of the evidence base". Nutrition, Metabolism and Cardiovascular Diseases 18 (6): 448–456. doi:10.1016/j.numecd.2008.02.005. ISSN 0939-4753.
  31. ↑ Remig, Valentina; Franklin, Barry; Margolis, Simeon; Kostas, Georgia; Nece, Theresa; Street, James C. (2010). "Trans Fats in America: A Review of Their Use, Consumption, Health Implications, and Regulation". Journal of the American Dietetic Association 110 (4): 585–592. doi:10.1016/j.jada.2009.12.024. ISSN 0002-8223.
  32. ↑ Te Morenga, L. A.; Howatson, A. J.; Jones, R. M.; Mann, J. (2014). "Dietary sugars and cardiometabolic risk: systematic review and meta-analyses of randomized controlled trials of the effects on blood pressure and lipids". American Journal of Clinical Nutrition 100 (1): 65–79. doi:10.3945/ajcn.113.081521. ISSN 0002-9165.
  33. ↑ "Wylie-Rosett2002"
  34. ↑ Micha, Renata; Michas, Georgios; Mozaffarian, Dariush (2012). "Unprocessed Red and Processed Meats and Risk of Coronary Artery Disease and Type 2 Diabetes – An Updated Review of the Evidence". Current Atherosclerosis Reports 14 (6): 515–524. doi:10.1007/s11883-012-0282-8. ISSN 1523-3804. PMC 3483430. PMID 23001745.
  35. ↑ Mukamal, Kenneth J.; Chen, Chiung M.; Rao, Sowmya R.; Breslow, Rosalind A. (2010). "Alcohol Consumption and Cardiovascular Mortality Among U.S. Adults, 1987 to 2002". Journal of the American College of Cardiology 55 (13): 1328–1335. doi:10.1016/j.jacc.2009.10.056. ISSN 0735-1097.
  36. ↑ World Health Organization (2011). Global Status Report on Alcohol and Health. World Health Organization. ISBN 978-92-4-156415-1.
  37. 1 2 3 Mariachiara Di Cesare, Young-Ho Khang, Perviz Asaria, Tony Blakely, Melanie J. Cowan, Farshad Farzadfar, Ramiro Guerrero, Nayu Ikeda, Catherine Kyobutungi, Kelias P. Msyamboza, Sophal Oum, John W. Lynch, Michael G. Marmot & Majid Ezzati (February 2013). "Inequalities in non-communicable diseases and effective responses". Lancet 381 (9866): 585–597. doi:10.1016/S0140-6736(12)61851-0. PMID 23410608.
  38. ↑ J. P. Mackenbach, A. E. Cavelaars, A. E. Kunst & F. Groenhof (July 2000). "Socioeconomic inequalities in cardiovascular disease mortality; an international study". European Heart Journal 21 (14): 1141–1151. doi:10.1053/euhj.1999.1990. PMID 10924297.
  39. ↑ Alexander M. Clark, Marie DesMeules, Wei Luo, Amanda S. Duncan & Andy Wielgosz (November 2009). "Socioeconomic status and cardiovascular disease: risks and implications for care". Nature reviews. Cardiology 6 (11): 712–722. doi:10.1038/nrcardio.2009.163. PMID 19770848.
  40. ↑ World Health Organization (2008). Closing the Gap in a Generation: Health Equity Through Action on the Social Determinants of Health : Commission on Social Determinants of Health Final Report. World Health Organization. pp. 26–. ISBN 978-92-4-156370-3.
  41. 1 2 Khallaf, Mohamed (2011). The Impact of Air Pollution on Health, Economy, Environment and Agricultural Sources. InTech. pp. 69–92. ISBN 978-953-307-528-0.
  42. 1 2 3 4 Franchini M, Mannucci PM (2012). "Air pollution and cardiovascular disease". Thrombosis Research 129 (3): 230–4. doi:10.1016/j.thromres.2011.10.030. PMID 22113148.
  43. 1 2 "Cardiovascular Effects of Ambient Particulate Air Pollution Exposure". Circulation 121 (25): 2755–65. 2010. doi:10.1161/CIRCULATIONAHA.109.893461. PMC 2924678. PMID 20585020.
  44. 1 2 Tunstall-Pedoe, H. (2011). "Cardiovascular Risk and Risk Scores: ASSIGN, Framingham, QRISK and others: how to choose". Heart 97 (6): 442–444. doi:10.1136/hrt.2010.214858. ISSN 1355-6037.
  45. ↑ World Health Organization (2007). Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Cardiovascular Risk. World Health Organization. ISBN 978-92-4-154717-8.
  46. ↑ Hernandez, Adrian V.; van Staa, Tjeerd-Pieter; Gulliford, Martin; Ng, Edmond S.-W.; Goldacre, Ben; Smeeth, Liam (2014). "Prediction of Cardiovascular Risk Using Framingham, ASSIGN and QRISK2: How Well Do They Predict Individual Rather than Population Risk?". PLoS ONE 9 (10): e106455. doi:10.1371/journal.pone.0106455. ISSN 1932-6203.
  47. ↑ Hlatky, M. A.; Greenland, P.; Arnett, D. K.; Ballantyne, C. M.; Criqui, M. H.; Elkind, M. S.V.; Go, A. S.; Harrell, F. E.; Hong, Y.; Howard, B. V.; Howard, V. J.; Hsue, P. Y.; Kramer, C. M.; McConnell, J. P.; Normand, S.-L. T.; O'Donnell, C. J.; Smith, S. C.; Wilson, P. W.F. (2009). "Criteria for Evaluation of Novel Markers of Cardiovascular Risk: A Scientific Statement From the American Heart Association". Circulation 119 (17): 2408–2416. doi:10.1161/CIRCULATIONAHA.109.192278. ISSN 0009-7322.
  48. ↑ Eckel, Robert H; Cornier, Marc-Andre (2014). "Update on the NCEP ATP-III emerging cardiometabolic risk factors". BMC Medicine 12 (1): 115. doi:10.1186/1741-7015-12-115. ISSN 1741-7015.
  49. ↑ Bertazzo, S. et al. Nano-analytical electron microscopy reveals fundamental insights into human cardiovascular tissue calcification. Nature Materials 12, 576–583 (2013).
  50. ↑ Vanhecke TE, Miller WM, Franklin BA, Weber JE, McCullough PA (Oct 2006). "Awareness, knowledge, and perception of heart disease among adolescents". Eur J Cardiovasc Prev Rehabil. 13 (5): 718–23. doi:10.1097/01.hjr.0000214611.91490.5e. PMID 17001210.
  51. ↑ Highlander P, Shaw GP (2010). "Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics". Ther Adv Cardiovasc Dis. 4 (1): 43–54. doi:10.1177/1753944709354305.
  52. ↑ NPS Medicinewise (1 March 2011). "NPS Prescribing Practice Review 53: Managing lipids". Retrieved 1 August 2011.
  53. ↑ Kvan E., Pettersen K.I., Sandvik L., Reikvam A. (2007). "High mortality in diabetic patient with acute myocardial infarction: cardiovascular co-morbidities contribute most to the high risk". Int J Cardiol 121 (2): 184–188. doi:10.1016/j.ijcard.2006.11.003.
  54. ↑ Norhammar A., Malmberg K., Diderhol E., Lagerqvist B., Lindahl B., Ryde; et al. (2004). "Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J". Am Coll Cardiol 43 (4): 585–591. doi:10.1016/j.jacc.2003.08.050.
  55. ↑ DECODE , European Diabetes Epidemiology Group (1999). "Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria". Lancet 354 (9179): 617–621. doi:10.1016/S0140-6736(98)12131-1. PMID 10466661.
  56. 1 2 Moyer, VA; U.S. Preventive Services Task Force (Oct 2, 2012). "Screening for coronary heart disease with electrocardiography: U.S. Preventive Services Task Force recommendation statement.". Annals of Internal Medicine 157 (7): 512–8. doi:10.7326/0003-4819-157-7-201210020-00514. PMID 22847227.
  57. ↑ Maron, B. J.; Friedman, R. A.; Kligfield, P.; Levine, B. D.; Viskin, S.; Chaitman, B. R.; Okin, P. M.; Saul, J. P.; Salberg, L.; Van Hare, G. F.; Soliman, E. Z.; Chen, J.; Matherne, G. P.; Bolling, S. F.; Mitten, M. J.; Caplan, A.; Balady, G. J.; Thompson, P. D. (15 September 2014). "Assessment of the 12-Lead ECG as a Screening Test for Detection of Cardiovascular Disease in Healthy General Populations of Young People (12–25 Years of Age): A Scientific Statement From the American Heart Association and the American College of Cardiology". Circulation 130 (15): 1303–1334. doi:10.1161/CIR.0000000000000025.
  58. ↑ Chou, Roger (17 March 2015). "Cardiac Screening With Electrocardiography, Stress Echocardiography, or Myocardial Perfusion Imaging: Advice for High-Value Care From the American College of Physicians". Annals of Internal Medicine 162 (6): 438. doi:10.7326/M14-1225.
  59. ↑ Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS (2006). "Multiple biomarkers for the prediction of first major cardiovascular events and death". N. Engl. J. Med. 355 (25): 2631–billy bob joe9. doi:10.1056/NEJMoa055373. PMID 17182988.
  60. ↑ Spence JD (2006). "Technology Insight: ultrasound measurement of carotid plaque—patient management, genetic research, and therapy evaluation". Nat Clin Pract Neurol 2 (11): 611–9. doi:10.1038/ncpneuro0324. PMID 17057748.
  61. 1 2 3 4 NHS Direct
  62. ↑ Ignarro, LJ; Balestrieri, ML; Napoli, C (Jan 15, 2007). "Nutrition, physical activity, and cardiovascular disease: an update.". Cardiovascular research 73 (2): 326–40. doi:10.1016/j.cardiores.2006.06.030. PMID 16945357.
  63. 1 2 Wang, X; Ouyang, Y; Liu, J; Zhu, M; Zhao, G; Bao, W; Hu, FB (Jul 29, 2014). "Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies.". BMJ (Clinical research ed.) 349: g4490. doi:10.1136/bmj.g4490. PMC 4115152. PMID 25073782.
  64. ↑ World Heart Federation (5 October 2011). "World Heart Federation: Cardiovascular disease risk factors". Retrieved 5 October 2011.
  65. ↑ The National Heart, Lung, and Blood Institute (NHLBI) (5 October 2011). "How To Prevent and Control Coronary Heart Disease Risk Factors – NHLBI, NIH". Retrieved 5 October 2011.
  66. ↑ Klatsky AL (May 2009). "Alcohol and cardiovascular diseases". Expert Rev Cardiovasc Ther 7 (5): 499–506. doi:10.1586/erc.09.22. PMID 19419257.
  67. ↑ McMahan, C. Alex; Gidding, Samuel S.; Malcom, Gray T.; Tracy, Richard E.; Strong, Jack P.; McGill, Henry C. (2006-10-01). "Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis". Pediatrics 118 (4): 1447–1455. doi:10.1542/peds.2006-0970. ISSN 1098-4275. PMID 17015535.
  68. ↑ Raitakari, Olli T.; Rönnemaa, Tapani; Järvisalo, Mikko J.; Kaitosaari, Tuuli; Volanen, Iina; Kallio, Katariina; Lagström, Hanna; Jokinen, Eero; Niinikoski, Harri (2005-12-13). "Endothelial function in healthy 11-year-old children after dietary intervention with onset in infancy: the Special Turku Coronary Risk Factor Intervention Project for children (STRIP)". Circulation 112 (24): 3786–3794. doi:10.1161/CIRCULATIONAHA.105.583195. ISSN 1524-4539. PMID 16330680.
  69. ↑ McTigue KM, Hess R, Ziouras J (September 2006). "Obesity in older adults: a systematic review of the evidence for diagnosis and treatment". Obesity (Silver Spring) 14 (9): 1485–97. doi:10.1038/oby.2006.171. PMID 17030958.
  70. ↑ Linden W, Stossel C, Maurice J (April 1996). "Psychosocial interventions for patients with coronary artery disease: a meta-analysis". Arch. Intern. Med. 156 (7): 745–52. doi:10.1001/archinte.1996.00440070065008. PMID 8615707.
  71. ↑ Thompson, D. R.; Ski, C. F. (2013). "Psychosocial interventions in cardiovascular disease - what are they?". European Journal of Preventive Cardiology 20 (6): 916–917. doi:10.1177/2047487313494031. ISSN 2047-4873.
  72. ↑ Wei, J; Rooks, C; Ramadan, R; Shah, AJ; Bremner, JD; Quyyumi, AA; Kutner, M; Vaccarino, V (15 July 2014). "Meta-analysis of mental stress-induced myocardial ischemia and subsequent cardiac events in patients with coronary artery disease.". The American journal of cardiology 114 (2): 187–92. doi:10.1016/j.amjcard.2014.04.022. PMID 24856319.
  73. ↑ Pelliccia, F; Greco, C; Vitale, C; Rosano, G; Gaudio, C; Kaski, JC (August 2014). "Takotsubo syndrome (stress cardiomyopathy): an intriguing clinical condition in search of its identity.". The American Journal of Medicine 127 (8): 699–704. doi:10.1016/j.amjmed.2014.04.004. PMID 24754972.
  74. ↑ Marshall, IJ; Wolfe, CD; McKevitt, C (Jul 9, 2012). "Lay perspectives on hypertension and drug adherence: systematic review of qualitative research.". BMJ (Clinical research ed.) 345: e3953. doi:10.1136/bmj.e3953. PMC 3392078. PMID 22777025.
  75. ↑ Dickinson, HO; Mason, JM; Nicolson, DJ; Campbell, F; Beyer, FR; Cook, JV; Williams, B; Ford, GA (February 2006). "Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials.". Journal of Hypertension 24 (2): 215–33. doi:10.1097/01.hjh.0000199800.72563.26. PMID 16508562.
  76. ↑ Abbott, RA; Whear, R; Rodgers, LR; Bethel, A; Thompson Coon, J; Kuyken, W; Stein, K; Dickens, C (May 2014). "Effectiveness of mindfulness-based stress reduction and mindfulness based cognitive therapy in vascular disease: A systematic review and meta-analysis of randomised controlled trials.". Journal of psychosomatic research 76 (5): 341–51. doi:10.1016/j.jpsychores.2014.02.012. PMID 24745774.
  77. ↑ Moyer, VA; U.S. Preventive Services Task Force (Sep 4, 2012). "Behavioral counseling interventions to promote a healthful diet and physical activity for cardiovascular disease prevention in adults: U.S. Preventive Services Task Force recommendation statement.". Annals of Internal Medicine 157 (5): 367–71. doi:10.7326/0003-4819-157-5-201209040-00486. PMID 22733153.
  78. ↑ Li, C; Lv, Z; Shi, Z; Zhu, Y; Wu, Y; Li, L; Iheozor-Ejiofor, Z (Aug 15, 2014). "Periodontal therapy for the management of cardiovascular disease in patients with chronic periodontitis.". The Cochrane database of systematic reviews 8: CD009197. doi:10.1002/14651858.CD009197.pub2. PMID 25123257.
  79. ↑ Seron, P; Lanas, F; Pardo Hernandez, H; Bonfill Cosp, X (Aug 13, 2014). "Exercise for people with high cardiovascular risk.". The Cochrane database of systematic reviews 8: CD009387. doi:10.1002/14651858.CD009387.pub2. PMID 25120097.
  80. ↑ Walker C, Reamy BV (April 2009). "Diets for cardiovascular disease prevention: what is the evidence?". Am Fam Physician 79 (7): 571–8. PMID 19378874.
  81. ↑ Nordmann, AJ; Suter-Zimmermann, K; Bucher, HC; Shai, I; Tuttle, KR; Estruch, R; Briel, M (September 2011). "Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors.". The American Journal of Medicine 124 (9): 841–51.e2. doi:10.1016/j.amjmed.2011.04.024. PMID 21854893.
  82. ↑ Sacks FM, Svetkey LP, Vollmer WM; et al. (January 2001). "Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group". N. Engl. J. Med. 344 (1): 3–10. doi:10.1056/NEJM200101043440101. PMID 11136953.
  83. ↑ Obarzanek E, Sacks FM, Vollmer WM; et al. (July 2001). "Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial". Am. J. Clin. Nutr. 74 (1): 80–9. PMID 11451721.
  84. ↑ Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi T, Azizi F (December 2005). "Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome". Diabetes Care 28 (12): 2823–31. doi:10.2337/diacare.28.12.2823. PMID 16306540.
  85. ↑ Logan AG (March 2007). "DASH Diet: time for a critical appraisal?". Am. J. Hypertens. 20 (3): 223–4. doi:10.1016/j.amjhyper.2006.10.006. PMID 17324730.
  86. ↑ Threapleton, D. E.; Greenwood, D. C.; Evans, C. E. L.; Cleghorn, C. L.; Nykjaer, C.; Woodhead, C.; Cade, J. E.; Gale, C. P.; Burley, V. J. (19 December 2013). "Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis". BMJ 347 (dec19 2): f6879–f6879. doi:10.1136/bmj.f6879. PMC 3898422. PMID 24355537.
  87. ↑ "Fats and fatty acids in human nutrition Report of an expert consultation". World Health Organization. WHO/FAO. Retrieved 20 December 2014.
  88. 1 2 3 Willett, WC (July 2012). "Dietary fats and coronary heart disease.". Journal of internal medicine 272 (1): 13–24. doi:10.1111/j.1365-2796.2012.02553.x. PMID 22583051.
  89. 1 2 3 Chowdhury, Rajiv; Warnakula, Samantha; Kunutsor, Setor; Crowe, Francesca; Ward, Heather A.; Johnson, Laura; Franco, Oscar H.; Butterworth, Adam S.; Forouhi, Nita G.; Thompson, Simon G.; Khaw, Kay-Tee; Mozaffarian, Dariush; Danesh, John; Di Angelantonio, Emanuele (18 March 2014). "Association of Dietary, Circulating, and Supplement Fatty Acids With Coronary Risk". Annals of Internal Medicine 160 (6): 398–406. doi:10.7326/M13-1788. PMID 24723079.
  90. 1 2 Ramsden, CE; Zamora, D; Leelarthaepin, B; Majchrzak-Hong, SF; Faurot, KR; Suchindran, CM; Ringel, A; Davis, JM; Hibbeln, JR (Feb 4, 2013). "Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis.". BMJ (Clinical research ed.) 346: e8707. doi:10.1136/bmj.e8707. PMID 23386268.
  91. 1 2 "Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies". BMJ 351 (h3978). Aug 12, 2015. doi:10.1136/bmj.h3978. PMC 4532752. PMID 26268692.
  92. ↑ Hooper, L; Summerbell, CD; Thompson, R; Sills, D; Roberts, FG; Moore, HJ; Davey Smith, G (May 16, 2012). "Reduced or modified dietary fat for preventing cardiovascular disease.". Cochrane database of systematic reviews (Online) 5: CD002137. doi:10.1002/14651858.CD002137.pub3. PMID 22592684.
  93. ↑ Siri-Tarino Patty W, Sun Qi, Hu Frank B, Krauss Ronald M (2010). "Saturated fat, carbohydrate, and cardiovascular disease". American Journal of Clinical Nutrition 91 (3): 502–509. doi:10.3945/ajcn.2008.26285. PMC 2824150. PMID 20089734.
  94. ↑ Micha, R; Mozaffarian, D (October 2010). "Saturated fat and cardiometabolic risk factors, coronary heart disease, stroke, and diabetes: a fresh look at the evidence.". Lipids 45 (10): 893–905. doi:10.1007/s11745-010-3393-4. PMC 2950931. PMID 20354806.
  95. ↑ Astrup, A; Dyerberg, J; Elwood, P; Hermansen, K; Hu, FB; Jakobsen, MU; Kok, FJ; Krauss, RM; Lecerf, JM; LeGrand, P; Nestel, P; Risérus, U; Sanders, T; Sinclair, A; Stender, S; Tholstrup, T; Willett, WC (April 2011). "The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010?". The American Journal of Clinical Nutrition 93 (4): 684–8. doi:10.3945/ajcn.110.004622. PMC 3138219. PMID 21270379.
  96. ↑ Rizos, EC; Ntzani, EE; Bika, E; Kostapanos, MS; Elisaf, MS (Sep 12, 2012). "Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis.". JAMA: the Journal of the American Medical Association 308 (10): 1024–33. doi:10.1001/2012.jama.11374. PMID 22968891.
  97. 1 2 Taylor, RS; Ashton, KE; Moxham, T; Hooper, L; Ebrahim, S (Jul 6, 2011). "Reduced dietary salt for the prevention of cardiovascular disease.". Cochrane database of systematic reviews (Online) (7): CD009217. doi:10.1002/14651858.CD009217. PMID 21735439.
  98. 1 2 He, F J; MacGregor G A (2011). "Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials" (PDF). The Lancet 378 (9789): 380–382. doi:10.1016/S0140-6736(11)61174-4. PMID 21803192.
  99. ↑ Paterna, S; Gaspare P; Fasullo S; Sarullo FM; Di Pasquale P (2008). "Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend?". Clin Sci (Lond) 114 (3): 221–230. doi:10.1042/CS20070193. PMID 17688420.
  100. 1 2 Bochud, M; Marques-Vidal, P; Burnier, M; Paccaud, F (2012). "Dietary Salt Intake and Cardiovascular Disease: Summarizing the Evidence". Public Health Reviews 33: 530–552.
  101. ↑ Cook, N R; et al. (2007). "Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP)". BMJ 334 (7599): 334. doi:10.1136/bmj.39147.604896.55. PMC 1857760. PMID 17449506.
  102. ↑ Berger, JS; Lala, A; Krantz, MJ; Baker, GS; Hiatt, WR (July 2011). "Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials.". American Heart Journal 162 (1): 115–24.e2. doi:10.1016/j.ahj.2011.04.006. PMID 21742097.
  103. ↑ "Final Recommendation Statement Aspirin for the Prevention of Cardiovascular Disease: Preventive Medication". http://www.uspreventiveservicestaskforce.org/. March 2009. Retrieved 15 January 2015. External link in |website= (help)
  104. 1 2 Gutierrez, J; Ramirez, G; Rundek, T; Sacco, RL (Jun 25, 2012). "Statin Therapy in the Prevention of Recurrent Cardiovascular Events: A Sex-Based Meta-analysisStatin Therapy to Prevent Recurrent CV Events.". Archives of Internal Medicine 172 (12): 909–19. doi:10.1001/archinternmed.2012.2145. PMID 22732744.
  105. ↑ Taylor, F; Huffman, MD; Macedo, AF; Moore, TH; Burke, M; Davey Smith, G; Ward, K; Ebrahim, S (Jan 31, 2013). "Statins for the primary prevention of cardiovascular disease.". Cochrane database of systematic reviews (Online) 1: CD004816. doi:10.1002/14651858.CD004816.pub5. PMID 23440795.
  106. ↑ Downs, JR; O'Malley, PG (18 August 2015). "Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline.". Annals of Internal Medicine 163 (4): 291–7. doi:10.7326/m15-0840. PMID 26099117.
  107. ↑ Francis, DP (May 19, 2011). "Duration and magnitude of the effect of a single statin tablet in primary prevention of cardiovascular events.". International journal of cardiology 149 (1): 102–7. doi:10.1016/j.ijcard.2010.11.013. PMID 21183232.
  108. ↑ Keene, D; Price, C; Shun-Shin, MJ; Francis, DP (Jul 18, 2014). "Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.". BMJ (Clinical research ed.) 349: g4379. doi:10.1136/bmj.g4379. PMC 4103514. PMID 25038074.
  109. ↑ American College of Chest Physicians; American Thoracic Society (September 2013), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation (American College of Chest Physicians and American Thoracic Society), retrieved 6 January 2013
  110. ↑ Bhupathiraju, SN; Tucker, KL (Aug 17, 2011). "Coronary heart disease prevention: nutrients, foods, and dietary patterns.". Clinica chimica acta; international journal of clinical chemistry 412 (17–18): 1493–514. doi:10.1016/j.cca.2011.04.038. PMID 21575619.
  111. ↑ Myung, SK; Ju, W; Cho, B; Oh, SW; Park, SM; Koo, BK; Park, BJ; for the Korean Meta-Analysis (KORMA) Study, Group (Jan 18, 2013). "Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials.". BMJ (Clinical research ed.) 346: f10. doi:10.1136/bmj.f10. PMC 3548618. PMID 23335472.
  112. ↑ Fortmann, SP; Burda, BU; Senger, CA; Lin, JS; Whitlock, EP (Nov 12, 2013). "Vitamin and Mineral Supplements in the Primary Prevention of Cardiovascular Disease and Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force.". Annals of Internal Medicine 159 (12): 824–34. doi:10.7326/0003-4819-159-12-201312170-00729. PMID 24217421.
  113. ↑ Bruckert, E; Labreuche, J; Amarenco, P (June 2010). "Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis". Atherosclerosis 210 (2): 353–61. doi:10.1016/j.atherosclerosis.2009.12.023. PMID 20079494.
  114. ↑ Lavigne, PM; Karas, RH (Jan 29, 2013). "The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.". Journal of the American College of Cardiology 61 (4): 440–6. doi:10.1016/j.jacc.2012.10.030. PMID 23265337.
  115. ↑ Jee SH, Miller ER III, Guallar E; et al. (2002). "The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials". Am J Hypertens 15 (8): 691–696. doi:10.1016/S0895-7061(02)02964-3. PMID 12160191.
  116. ↑ Zipes DP, Camm AJ, Borggrefe M; et al. (2012). "ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society". Circulation 114 (10): e385–e484. doi:10.1161/CIRCULATIONAHA.106.178233. PMID 16935995.
  117. ↑ Kwak, SM; Myung, SK; Lee, YJ; Seo, HG; for the Korean Meta-analysis Study, Group (Apr 9, 2012). "Efficacy of Omega-3 Fatty Acid Supplements (Eicosapentaenoic Acid and Docosahexaenoic Acid) in the Secondary Prevention of Cardiovascular Disease: A Meta-analysis of Randomized, Double-blind, Placebo-Controlled Trials.". Archives of Internal Medicine 172 (9): 686. doi:10.1001/archinternmed.2012.262. PMID 22493407.
  118. ↑ "WHO Disease and injury country estimates". World Health Organization. 2009. Retrieved Nov 11, 2009.
  119. ↑ Indian Heart Association Why South Asians Facts Web. 29 April 2015. <http://indianheartassociation.org/why-indians-why-south-asians/overview/>
  120. ↑ Morris J. N., Crawford Margaret D. (1958). "Coronary Heart Disease and Physical Activity of Work". British Medical Journal 2 (5111): 1485–1496. doi:10.1136/bmj.2.5111.1485. PMC 2027542. PMID 13608027.
  121. ↑ Karakas M, Koenig W (December 2009). "CRP in cardiovascular disease". Herz 34 (8): 607–13. doi:10.1007/s00059-009-3305-7. PMID 20024640.
  122. ↑ 20448212
  123. ↑ Venuraju SM, Yerramasu A, Corder R, Lahiri A (May 2010). "Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity". J. Am. Coll. Cardiol. 55 (19): 2049–61. doi:10.1016/j.jacc.2010.03.013. PMID 20447527.
  124. ↑ Andraws R, Berger JS, Brown DL (Jun 2005). "Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials". JAMA 293 (21): 2641–7. doi:10.1001/jama.293.21.2641. PMID 15928286.
  125. ↑ Dominguez-Rodriguez, Alberto (January 2012). "Melatonin and Cardiovascular Disease: Myth or Reality?". Rev Esp Cardiol 65: 215–218.

External links

This article is issued from Wikipedia - version of the Monday, February 15, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.